Doxorubicin Market Projected to Grow at a Steady Pace by 2025

Doxorubicin is the generic drug name for anti-cancer chemotherapy drug Adriamycin and Rubex. Doxorubicin is an anthracycline antibiotic and belongs to the group of anti-cancer medication known as antineoplastic and is made from the natural product produced by bacterium Streptomyces peucetius var. caesius. It is used for the treatment of different types of cancer including breast, stomach, ovary, bone, testicles, bladder, lung, soft tissue, osteogenic sarcoma, Wilms’ tumor, and Hodgkin’s and non-Hodgkin’s lymphomas. It is also used less commonly in the treatment of squamous cell carcinomas of the head and neck. Vagina and cervix, refractory multiple myeloma, and neuroblastoma. Doxorubicin inhibits and or slows the rate of proliferation of cancerous cells by intercalating between the base pairs in the DNA helix, thereby preventing DNA replication and inhibiting protein synthesis. This medication is available in injection solution and lyophilized powder form and is administered intravenously either through peripheral inserted central line catheters (PICC) or central venous catheters (CVC). The dosage of this medication depends on the type and severity of cancer, and type of other medication used during treatments and is most commonly scheduled at 21 days of every dosage.

Report Overview and TOC @ https://www.transparencymarketresearch.com/doxorubicin-market.html

The global doxorubicin market is anticipated to expand at a higher growth rate owing to increasing prevalence of cancer patients worldwide. According to the WHO, cancer is the leading cause of death globally, accounting 8.8 million deaths in 2015. The number of new cases is expected to increase by 70% in the next two decades. The global market for this drug is also expected to be driven by increasing use in the treatment of HIV-associated Kaposi sarcoma. HIV-associated Kaposi sarcoma has markedly increased in countries in Africa and the West in the last two decades. On the other hand, doxorubicin medication can cause life threatening conditions such as heart failure during therapy or sometimes after months or years after treatment. Additionally, it can cause side effects such as nausea, vomiting, diarrhea, loss of appetite, and reddish urine after one to two days of treatment. These side effects, specifically cardio toxicity, imposes a limitation on the use of doxorubicin and creates an opportunity for development of lipid based (liposome) formulations with improved therapeutic index of conventional doxorubicin.

Request brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=26138

The global doxorubicin drug market has been segmented based on drug formulation, type of cancer, distribution channel, and region. In terms of drug formulation, the market has been segmented into lyophilized powder and doxorubicin injection. It is administered through the vein either peripherally or through central venous catheter. Based on type of cancer, the market has been segmented into lung cancer, Hodgkin’s and non-Hodgkin’s cancer, breast cancer, prostate cancer, ovary cancer, stomach cancer, leukemia, and others. Lung and breast cancer are expected to be major segments of the global doxorubicin market. This medication is available in hospital pharmacy, retail pharmacy, and online pharmacy. Of these distribution channels, hospital pharmacy is projected to be the key segment during the forecast period.

for Specific and Customized requirements@ https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=26138

In terms of region, the global doxorubicin market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Europe is anticipated to dominate the global doxorubicin market owing to highest number of cancer patients and favorable medical reimbursement policies. North America is the second leading market for doxorubicin. Asia Pacific is projected to be the fastest growing market during the forecast period driven by increasing rate of diagnosis of cancer patients and improving health care accessibility and infrastructure.

Key players operating in the global doxorubicin market are Pfizer, Inc., Johnson & Johnson, Accord Healthcare, Novartis AG, Thymoorgan Pharmazie GmbH, Sun Pharmaceutical Industries Ltd., Allergan, Inc., Meiji Seika Pharma Co., Merrimack Pharmaceuticals, Inc., and Dr. Reddy’s Laboratories Ltd., among others.

Pre Book full report@ https://www.transparencymarketresearch.com/checkout.php?rep_id=26138<ype=S

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

About TMR

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Contact

Transparency Market Research
State Tower
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com
TMR Blog: http://www.theglobalhealthnews.com/

This release was published on openPR.